{"id":"W2747211312","doi":"10.1200/jco.2017.35.15_suppl.tps7068","title":"A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Internal medicine; Surgery; Gastroenterology; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003157231,0.002877771,0.003128283,0.000706248,0.0006473936,0.001322634,0.001519948,0.002111281,0.00703578],"category_scores_gemma":[0.001403209,0.0009228601,0.002241734,0.000510392,0.001857575,0.001853167,0.0005076501,0.005250736,0.001745728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00118625,"about_ca_system_score_gemma":0.002825195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001383762,"about_ca_topic_score_gemma":0.004097414,"domain_scores_codex":[0.9993067,0.000318804,0.0000282434,0.0001269564,0.00005415454,0.0001650972],"domain_scores_gemma":[0.9984691,0.0002107454,0.0002693281,0.0001078618,0.00007570755,0.0008672677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9042717,0.05816324,0.002012697,0.0003819065,0.0008240127,0.0001265681,0.0001580644,0.0009543603,0.01043949,0.0001622616,0.002868335,0.01963746],"study_design_scores_gemma":[0.8496743,0.1460114,0.002333138,0.00001131906,0.0002326352,0.00005475048,0.00002171189,0.0004457812,0.0005330531,0.0001248246,0.0005383427,0.0000187297],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847377,0.001736959,0.0007624924,0.0009709927,0.0003290284,0.006861716,0.002215918,0.0002288645,0.002156351],"genre_scores_gemma":[0.9737188,0.001775743,0.003124073,0.002840045,0.0005270999,0.009428865,0.004196824,0.00007641107,0.004312166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00703578,"threshold_uncertainty_score":0.02353704,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1725306022999198,"score_gpt":0.5040483404656478,"score_spread":0.331517738165728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}